1. Home
  2. Investors
  3. News

News

To receive future news releases direct to your inbox, subscribe by emailing ir@resverlogix.com.

Historical news and financial information can also be found at www.sedar.com under the Company’s profile.

2019 2018 2017 2016 2015 2014
Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
September 30, 2019
Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan
September 27, 2019
Resverlogix to Host BETonMACE Webcast and Conference Call
September 26, 2019
Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association’s Scientific Sessions 2019
September 23, 2019
Resverlogix Provides Update on BETonMACE Phase 3 Trial
September 16, 2019
Resverlogix Announces Annual and Special Meeting of Shareholders
August 22, 2019
Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019
August 14, 2019
Resverlogix Announces Loan Reduction and Extension
August 2, 2019
Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics
July 15, 2019
Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
July 8, 2019
Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial
June 12, 2019
Resverlogix Announces Participation at Leading, International Scientific Conferences
June 10, 2019
Resverlogix Announces Closing of $15 Million Offering
June 7, 2019
Resverlogix Announces Pricing of Unit Offering
May 15, 2019
Resverlogix Announces Proposed Offering of Units
May 14, 2019
Resverlogix Announces Publication on Apabetalone in High-Impact American Journal of Respiratory and Critical Care Medicine (AJRCCM)
May 6, 2019
Resverlogix Announces 3-Month Loan Extension
May 2, 2019
Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
April 18, 2019
Resverlogix Announces $15.1 Million of Private Placements
April 1, 2019
Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases
April 1, 2019
Resverlogix Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 Study of Apabetalone
March 27, 2019
Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in Pulmonary Arterial Hypertension Led by Quebec Heart and Lung Institute – Laval University Researcher
March 18, 2019
Resverlogix Announces Participation at Prominent Industry and Investor Conferences
March 11, 2019
Resverlogix Closes $6.6 Million Private Placement with Shenzhen Hepalink
January 31, 2019